[Nilotinib treatment for imatinib resistant or intolerant chronic myelogenous leukemia.].

Aihua Wang, Li Zhou, Jianhua You, Li Wang, Junmin Li, Jiong Hu, Zhixiang ShenPubMed 2010

Abstract

Nilotinib is a more effective and safe treatment option for imatinib-resistant or -intolerant CML-CP patients.
BibTeX
@inproceedings{wang2010nilotinib,
  author = {Aihua Wang and Li Zhou and Jianhua You and Li Wang and Junmin Li and Jiong Hu and Zhixiang Shen},
  title = {{[Nilotinib treatment for imatinib resistant or intolerant chronic myelogenous leukemia.].}},
  booktitle = {PubMed},
  year = {2010},
}

Loading related content...

Figure